Neuropatia Periférica em Pacientes com Câncer Colorretal em Tratamento com Oxaliplatina

  • Helena Maria de Cerqueira Mathias Fisioterapeuta, Pós-graduanda da Universidade Salvador (UNIFACS), Salvador- BA, Brasil.
  • Maria Cecília Mathias Machado Acadêmica de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador-BA, Brasil.
  • Adriano Celso Rodrigues Fisioterapeuta, Especialista em Fisioterapia Traumatortopédica pela Universidade Gama Filho, Salvador-BA, Brasil.
Palavras-chave: Neoplasias Colorretais, Quimioterapia, Síndromes Neurotóxicas, Compostos de Platina, Polineuropatias, Polineuropatia Paraneoplásica

Resumo

Introdução. A neuropatia periférica representa uma das principais queixas dos pacientes com câncer colorretal submetidos à quimiotera­pia com oxaliplatina, sendo necessária uma maior compreensão sobre o tema pela comunidade de saúde. Objetivo. Revisar a literatura re­ferente à ocorrência de neuropatia periférica secundária à oxaliplatina em pacientes com câncer colorretal. Método. Pesquisa realizada nas bases de dados Medline e Science Direct, com período de coleta entre novembro de 2010 a fevereiro de 2011. Foram utilizados artigos cien­tíficos publicados nos últimos seis anos sobre o tema, sendo excluídos artigos de revisão de literatura e estudos experimentais em laborató­rio. Resultados. Após a pesquisa, foram selecionados 29 artigos para compor esse estudo, todos no idioma inglês. Nos artigos selecionados, observou-se que as principais manifestações clínicas descritas foram parestesia distal, disestesia perioral e laringofaríngea, incapacidade funcional, diminuição ou ausência de reflexos tendíneos, hipersensibi­lidade ao frio, dor e contração muscular. Conclusões. A frequência de neuropatia periférica em pacientes com câncer colorretal submetidos à quimioterapia com oxaliplatina é significativamente alta. Dessa forma, é essencial que os profissionais de saúde estejam atentos aos possíveis efeitos adversos dessa droga. Recomendam-se novos estudos com a finalidade de facilitar a busca de estratégias de prevenção e tratamento para o mesmo.

Métricas

Carregando métricas...

Referências

Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005;5:116-26. http://dx.doi.org/10.1186/1471-2407-5-116

Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluourouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25(16):2205-11. http://dx.doi.org/10.1200/JCO.2006.08.6652

Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer. The Oncologist 2007;12(3):312-9. http://dx.doi.org/10.1634/theoncologist.12-3-312

Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Seminars in Oncology 2002;29(15):21-33. http://dx.doi.org/10.1053/sonc.2002.35525

Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20(7):1767-74. http://dx.doi.org/10.1200/JCO.2002.07.056

Thierry A, Boni C, Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Improved Overall Survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II and III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16. http://dx.doi.org/10.1200/JCO.2008.20.6771

Mathias C, Feher O, Coutinho A, Paulo M, Hoff P. Manual de Condutas da Sociedade Brasileira de Oncologia Clinica. São Paulo; 2007.

Hill A, Bergin P, Hanning F, Thompson P, Findlay M, Damianovich D, et al. Detecting acute neurotoxicity durind platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer

;10(451):1471-2407.

Park S, Lin C, Krishnan A, Goldstein D, Friedlander L, Kiernan M. Oxaliplatin- induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009;132:2712-23. http://dx.doi.org/10.1093/brain/awp219

Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, et al. Folfox-4 stop and go and capecitabine manteinance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006;70:345-50. http://dx.doi.org/10.1159/000098107

Baek K, Lee J, Park S, Park J, Park Y, Lim H, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010;42(4):185-90. http://dx.doi.org/10.4143/crt.2010.42.4.185

Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-204. http://dx.doi.org/10.1200/JCO.2006.08.2974

Argyriou A, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos M, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007;46:1131-7. http://dx.doi.org/10.1080/02841860701355055

Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 2010;15:82-7. http://dx.doi.org/10.1007/s10147-009-0015-3

Chay WY, Tan SH, Lo YL, Ong YK, Ng HC, Gao F, et al. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia- Pac J Clin Oncol 2010;6:270-7. http://dx.doi.org/10.1111/j.17437563.2010.01344.x

Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne LB, et al. Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway. Clin Cancer Res 2007;13(21):6359-68. http://dx.doi.org/10.1158/1078-0432.CCR-07-0660

Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C. Persistence of high-dose Oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006;56:13-6. http://dx.doi.org/10.1159/000094376

Grothey A. Clinical Management of oxaliplatin-associated neurotoxicity. Clin Colorec Cancer 2005;5(1):38-46. http://dx.doi.org/10.3816/CCC.2005.s.006

Pasetto LM, D’Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: How and why? Crit Rev Oncol/ Hematol 2006;59:159-168.

Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepere C, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study. Pain 2009;144:245-52. http://dx.doi.org/10.1016/j.pain.2009.03.024

Grothey A, Nickcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2010;29(4):421-7. http://dx.doi.org/10.1200/JCO.2010.31.5911

Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006;67:2253-5. http://dx.doi.org/10.1212/01.wnl.0000249344.99671.d4

Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, et al. Efficacy of Goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Hindwai Pub Corp. 2009;2011:1093-110.

Binder A, Stengel M, Maag R, Wasner G, Schoch R, Moosig F, et al. Pain in oxaliplatin-induced neuropathy- Sensitization in the peripheral and central nociceptive system. Eur J Cancer 2007;43:2658-63. http://dx.doi.org/10.1016/j.ejca.2007.07.030

Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29:387-92. http://dx.doi.org/10.1002/mus.10559

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan M. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin- -induced neuropathy. Experimen Neurol 2010;227:120-27. http://dx.doi.org/10.1016/j.expneurol.2010.10.002

Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: Final results of a randomized, controlled, multicenter phase II study. Invest New Drugs. 2006;25:173-80. http://dx.doi.org/10.1007/s10637-006-9010-y

Nitrini R. Princípios fundamentais. In: Nitrini R, Bacheschi LA. A neurologia que todo médico deve saber. 2a ed. São Paulo: Atheneu; 2003, p.5-54. 29.Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, et al. The use of Vitamin E for the prevention chemotherapy- -induced peripheral neuropathy: results of a randomized phase III clinical trial. Supp Care Cancer 2010;10:1018-23.

Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.

Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutahtione S-Transferase P1 polymorphism (Ile 105 Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006;12(10):3050-6. http://dx.doi.org/10.1158/1078-0432.CCR-05-2076

Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, et al. Neurotoxicity of Folfox-4 as adjuvant treatment for patients with colon and gastric câncer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 2007;61:105-11. http://dx.doi.org/10.1007/s00280-007-0454-3

Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities of sensory nerve functions associated with oxaliplatin- nduced neurotoxicity. J Clin Oncol 2009;27(8):1243-9. http://dx.doi.org/10.1200/JCO.2008.19.3425

Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Supp Care Cancer 2011;11:1127-7.

Publicado
2013-09-30
Como Citar
Mathias, H. M. de C., Machado, M. C. M., & Rodrigues, A. C. (2013). Neuropatia Periférica em Pacientes com Câncer Colorretal em Tratamento com Oxaliplatina. Revista Neurociências, 21(3), 435-448. https://doi.org/10.34024/rnc.2013.v21.8164
Seção
Artigos de Revisão